Revolution Medicines, Inc.

Revolution Medicines, Inc. Earnings Recaps

RVMD Health Care 2 recaps
Next earnings: February 24, 2027 (estimated) · full calendar
Q3 2026 Nov 6, 2026

The stock fell 11.0% after earnings, signaling investor disappointment despite the U.S. approval and European regulatory progress. The excerpt highlights ambitious expansion plans and early launch execution but provides no launch or financial metrics, leaving commercial uptake and the outlook unclear.

Key takeaways
  • The FDA approved RAS(ON)Q (daraxonrasib) for specified patients with metastatic pancreatic cancer on August 26; the company says U.S. prescriptions began immediately.
  • The NCCN guidelines list RAS(ON)Q as a category 1 preferred subsequent therapy option in specified pancreatic cancer settings, including some beyond the FDA-approved indication.
  • The EMA’s CHMP adopted a positive opinion for the drug in previously treated metastatic pancreatic cancer; European Commission approval is still pending.
  • The FDA granted breakthrough therapy designation to investigational RAS(ON)Q plus chemotherapy in first-line metastatic pancreatic cancer and orphan drug designation to zoldonrasib for pancreatic cancer.
  • The company is conducting four additional global Phase 3 pancreatic cancer studies, including trials of zoldonrasib plus chemotherapy and a RAS(ON) inhibitor doublet.
Q2 2026 Aug 8, 2026

Shares rose modestly by 2.2% following the quarter, reflecting investor acknowledgment of meaningful progress in pancreatic cancer programs and regulatory milestones, although the reaction suggests some caution remains on near-term commercial ramp or broader pipeline clarity.

Key takeaways
  • Positive clinical data from the Phase III RASolute 302 trial demonstrated improvements in overall survival, progression-free survival, and quality of life for daraxonrasib in metastatic pancreatic cancer.
  • The FDA has accepted the new drug application for daraxonrasib, and the EMA has prioritized the drug for accelerated review under its Cancer Medicines Pathfinder initiative.
  • Expanded access program approved over 90% of requests, delivering daraxonrasib to more than 2,000 patients across nearly all U.S. states and Puerto Rico.
  • Commercial infrastructure for daraxonrasib’s U.S. launch is fully in place, including sales, medical affairs, and patient services.
  • Multiple Phase III studies continue enrolling for daraxonrasib and zoldonrasib in first-line and adjuvant pancreatic cancer settings, along with a novel combination trial, supporting a broad development strategy.